Lixte Biotechnology Holdings, Inc. Common Stock
LIXTLixte Biotechnology Holdings, Inc. is a biotechnology company focused on the discovery and development of targeted therapies for cancers and neurological disorders. The company utilizes its proprietary drug discovery platform to identify small-molecule compounds aimed at specific disease targets, with an emphasis on developing novel treatments with potential for clinical application.
Company News
LIXTE Biotechnology announced its participation in the DealFlow Discovery Conference on January 28-29, 2026, where CEO Geordan Pursglove will meet with investors. The company is advancing LB-100, a first-in-class PP2A inhibitor for cancer treatment, with proof-of-concept trials underway for ovarian clear cell carcinoma, metastatic colon cancer, a...
Spartan Capital Securities acted as exclusive placement agent for Lixte Biotechnology Holdings' $4.3 million registered direct offering. The clinical-stage pharmaceutical company focused on cancer treatments sold 1,051,342 common and pre-funded units to accredited investors at market prices, with proceeds to support general corporate purposes and...
LIXTE Biotechnology is advancing its cancer therapy pipeline with LB-100, a protein phosphatase 2A inhibitor targeting ovarian clear cell carcinoma, soft tissue sarcoma, and metastatic colon cancer, with potential trial results expected in late 2025.
LIXTE Biotechnology Holdings, Inc. has filed a request to withdraw its Registration Statement on Form S-1, as the company no longer intends to pursue a public offering at this time.
Clinical trial to test recent findings that show LIXTE’s lead clinical compound, LB-100, increases recognition of colon cancer cells by the immune system
